iECURE Inc. announced preliminary results from its ongoing clinical trial of ECUR-506, an experimental gene therapy for neonatal-onset ornithine transcarbamylase ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE